Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek® in adult patients with overactive bladder
"Purpose: Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek®) in adults diagnosed with OAB through a multicenter, prospective, non-inter...
Saved in:
Main Authors: | Jee Soo Park, Won Sik Jang, Jongchan Kim, Moon-Hwa Park, Won Sik Ham |
---|---|
Format: | Article |
Language: | English |
Published: |
Korean Urological Association
2025-01-01
|
Series: | Investigative and Clinical Urology |
Subjects: | |
Online Access: | https://www.icurology.org/pdf/10.4111/icu.20240278 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison Of Outcome And Side Effects Profile Of Treatment Of Overactive Bladder With Different Classes Of Drugs
by: Nazish Sarfraz, et al.
Published: (2023-12-01) -
An open-label, randomized, post-authorization study of mirabegron in Chinese participants with overactive bladder
by: Zhipeng Zhang, et al.
Published: (2025-01-01) -
The Management of Children and Adolescents with Overactive Bladder Refractory to Treatment with Parasacral Transcutaneous Electrical Nerve Stimulation
by: Carlos Eduardo Rocha Macedo, et al.
Published: (2025-01-01) -
The role of Kegel exercises in reducing involuntary loss of urine in Overactive Bladder and Mixed Urinary Inconti-nence
by: Lucian Șerbanescu, et al.
Published: (2025-01-01) -
Comparison of Use of Propiverine at 45 mg and Combined Treatment of Propiverine 30 mg and Mirabegron in Patients with Overactive Bladder Who did not Benefit from Propiverine 30 mg Treatment
by: İrfan Şafak Barlas, et al.
Published: (2024-04-01)